Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 40 от 222

Набира участници Фаза 3

HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).

X-Linked Protoporphyria (XLP) Erythropoietic Protoporphyria (EPP)

Trial status: Authorised 1. Change from baseline in daylight tolerance, as assessed by total hours spent in sunlight without pain and average time to first prodromal syndrome in sunlight., 2. Percent change from baseline in whole blood metal-free PPIX concentrations., 3. Plasma bitopertin concentrations. Safety and tolerability of bitopertin, as assessed by the incidence of treatmentemergent adverse events (TEAEs), vital signs, physical examinations, and clinical laboratory parameters.

Начало: 12.02.2026 Възраст: от 18 г.

Belgium, France, Germany +6 Disc Medicine Inc. 2025-523275-27-00

Набира участници Фаза 3

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Short Bowel Syndrome

The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.

Начало: 11.02.2026 Край: 28.02.2032 Възраст: 18–90 г.

Austria, Denmark, France +9 Zealand Pharma NCT07197944

Набира участници Фаза 3

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Breast Cancer

This is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative early breast cancer with residual disease after neoadjuvant chemotherapy

Начало: 10.02.2026 Край: 10.02.2031 Възраст: от 18 г.

China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University NCT07400523

Набира участници

Effect of PRP in Donor Semen During Cryoprervation

Sperm Cryodamage

Sperm cryopreservation allows the preservation of sperm biological function for long periods of time for later use in assisted reproductive techniques (ART). However, the freezing and thawing process causes structural and functional damage to sperm, leading to decreased motility and vitality, a loss of plasma membrane integrity and even DNA damage. In recent years, various strategies have been studied to protect sperm from cryodamage, including the optimization of freezing processes, the design of freezing devices, and improved freezing media. One possible measure to mitigate the cryodamage suffered by sperm is the addition of PRP, or platelet-rich plasma, to the freezing medium. In previous studies, PRP components have been shown to have positive effects on semen quality, improving motility, viability, and plasma membrane integrity after cryopreservation. In light of these positive results, this study will evaluate the possibility of incorporating PRP into sperm cryopreservation media and its potential future benefits for patients and clinical outcomes. To this end, each semen sample after a previous spermiogram will be aliquoted, and 0%, 1%, 2%, and 5% PRP will be added to the cryopreservation medium according to the sperm group to which the belong. A spermiogram will be performed after cryopreservation to assess various semen quality parameters, including sperm count, motility, morphology, vitality, and chromatin dispersion. The data must be processed through statistical analysis to obtain results that allow determining, primarily, whether there is a beneficial effect on sperm quality after sperm motility and sperm during cryopreservation with the addition of PRP.

Начало: 10.02.2026 Край: 30.01.2028 Възраст: 18–35 г.

Spain Instituto Valenciano de Infertilidad, IVI Alicante NCT07504575

Набира участници

DSLT for Reducing Medication in Glaucoma

Primary Open Angle Glaucoma Ocular Hypertension

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT. Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

Начало: 10.02.2026 Край: 26.01.2027

United States The Eye Institute of West Florida NCT07390890

Набира участници Фаза 2

A Study of Brenipatide in Adult Participants With Schizophrenia

Schizophrenia

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment period will last a maximum of 12 months, and the follow up period will last approximately 2 months. The length of time of your study participation may last up to approximately 15 months.

Начало: 10.02.2026 Край: 01.11.2027 Възраст: 18–55 г.

Argentina, Brazil, China +4 Eli Lilly and Company NCT07410507

Набира участници Фаза 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight Obesity

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

Начало: 10.02.2026 Край: 01.07.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +11 Eli Lilly and Company NCT07392190

Набира участници Фаза 1/2

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Neoplasms, Prostate

This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.

Начало: 10.02.2026 Край: 26.03.2030 Възраст: от 18 г.

Canada, Japan, United States GlaxoSmithKline NCT07332455

Набира участници

Self-balancing Personal Exoskeleton for SCI (WIP)

Spinal Cord Injuries Paraplegia and Tetraplegia

This study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).

Начало: 10.02.2026 Край: 30.04.2026 Възраст: от 18 г.

France Wandercraft NCT07536386

Набира участници Фаза 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive Obesity Overweight

The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.

Начало: 10.02.2026 Край: 01.04.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +9 Eli Lilly and Company NCT07369011

Набира участници

Relationships Between Nomophobia Levels and Perceived Stress, Body Image and Food Addiction Among University Students

Nomofobia Body Image Disturbance Body Image Body Image Disorder +3

The purpose of this study is to examine the effects of nomophobia levels on stress, food addiction, and body image among undergraduate students aged 18-30 at Bahçeşehir University, Faculty of Health Sciences. The primary questions it aims to answer are: * Is there a statistically significant relationship between nomophobia levels and perceived stress, food addiction, and body image among university students? * Is there a correlation between objective anthropometric data (body fat percentage, skeletal muscle mass) measured via Bioelectrical Impedance Analysis (BIA), waist/hip circumference measurements, and the individual's perceived body image?

Начало: 10.02.2026 Край: 01.05.2026 Възраст: 18–30 г.

Turkey (Türkiye) Bahçeşehir University NCT07518056

Набира участници Фаза 3

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Familial Pulmonary Fibrosis Interstitial Lung Abnormalities Interstitial Lung Diseases

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis. Participants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo. Participants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months. Doctors regularly test lung function and take chest scans to see if the treatment works. The results are compared between the 2 groups to see if nerandomilast helps. The doctors also check participants' health and take note of any unwanted effects.

Начало: 10.02.2026 Край: 23.05.2029 Възраст: от 40 г. Лечение

Argentina, Australia, Belgium +10 Boehringer Ingelheim NCT07201922

Набира участници Фаза 1

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500

Type 1 Diabetes

The goal of this clinical trial is to assess the safety of a new U500 insulin formulation and to determine how rapidly it is absorbed and how long it takes to act when administered intraperitoneally. The trial will be conducted in people with Type 1 Diabetes. The main questions it aims to answer are: Is the drug safe and tolerable when administered intraperitoneally? How fast is it absorbed, and how long does it take to act? Researchers will compare the investigational product (PI-U500) with Humulin R U500 administered intraperitoneally and Lyumjev U100 administered subcutaneously. Participants will undergo a 12-hour clamp procedure in which their blood glucose will be maintained stable via glucose infusion at variable rates after a single intraperitoneal injection of the insulin formulation.

Начало: 10.02.2026 Край: 01.09.2026 Възраст: 18–60 г.

United States Portal Diabetes, Inc. NCT07341373

Набира участници Фаза 2

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

Nasopharangeal Cancer

In this study, the investigators designed a randomized, open-label, phase II clinical trial for high-risk locally advanced nasopharyngeal carcinoma (T4 or N3 or EBV DNA ≥1500 copies/ml, AJCC 9th edition) that is sensitive to chemotherapy and PD-1 monoclonal antibody therapy. The trial compares sequential treatment with the TP regimen combined with PD-1 monoclonal antibody followed by concurrent chemoradiotherapy and PD-1 maintenance therapy versus capecitabine maintenance therapy. The aim is to provide high-quality clinical evidence for optimizing the treatment strategy for high-risk locally advanced nasopharyngeal carcinoma.

Начало: 10.02.2026 Край: 10.02.2033 Възраст: 18–70 г.

China Sun Yat-sen University NCT07392320

Набира участници

Impact of Dog Adoption and Training in Veterans With Post-traumatic Stress Symptoms and/or Other Mental Health Conditions

Posttraumatic Stress Symptoms Mental Health Conditions

The goal of this single-arm study is to learn if a dog adoption and training program can treat, prevent in \[describe participant population/primary condition; could include any of the following: sex/gender, age groups, healthy volunteers\]. The main questions it aims to answer are: * Does the dog adoption and training program decrease posttraumatic stress symptoms in veterans with self-reported posttraumatic stress symptoms? * Does the dog adoption and training program decrease stress and improve psychosocial health in veterans with self-reported posttraumatic stress symptoms? * Does the dog adoption and training program decrease inflammation, increase oxytocin, and change the structure and resting-state function of specific brain regions in veterans with self-reported posttraumatic stress symptoms? Participants will: * Attend eight one-hour professional dog training sessions within a 10-week period. * Visit the clinical research unit four times during the study for data collection.

Начало: 09.02.2026 Край: 01.12.2030 Възраст: от 18 г.

United States Florida Atlantic University NCT07542431

Набира участници Фаза 1/2

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

Retinitis Pigmentosa

This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP.

Начало: 09.02.2026 Край: 01.11.2028 Възраст: 18–65 г. Лечение

Australia Octant, Inc. NCT07408232

Набира участници Фаза 2

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

Cutaneous Melanoma Mucosal Melanoma

This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits. To improve the chance that melanoma will not recurr, new experimental combinations of a type of treatment called immunotherapy will be given before surgery.

Начало: 09.02.2026 Край: 01.01.2038 Възраст: от 18 г. Лечение

Australia Melanoma Institute Australia NCT06999980

Набира участници Фаза 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Osteoarthritis Overweight or Obesity

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

Начало: 09.02.2026 Край: 01.05.2028 Възраст: от 18 г.

Argentina, Belgium, Brazil +12 Eli Lilly and Company NCT07353931

Набира участници Фаза 2

A Phase 2 Open-label Multicenter study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children from 2 years to less than 18 years of age with generalized Myasthenia Gravis (gMG)

Generalized Myasthenia Gravis

Trial status: Authorised Change in Quantitative Myasthenia Gravis (QMG) score, Change in Myasthenia Gravis Activities of Daily Living (MG-ADL) score, Presence of anti-drug antibodies (ADAs) "Pharmacokinetic parameters, including maximum observed concentration (Cmax), area under the concentration-time curve (AUC), halflife (t1/2), clearance (CL) and volume of distribution at steady state (Vss)", Change from baseline in cluster of differentiation 20 (CD20)+ B-cell counts, "Incidence of treatment-emergent adverse events, treatment-emergent serious adverse events, adverse events of interest", Changes in laboratory parameters, Changes in vital signs

Начало: 09.02.2026

France, Italy, Poland +1 Amgen Inc. 2025-520993-20-00

Набира участници Фаза 3

A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis

Immune system diseases

Trial status: Authorised Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants with endoscopic improvement., Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving histologic endoscopic mucosal improvement., Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants with corticosteroid-free clinical remission., Proportion of participants with no bowel urgency., Pivotal Maintenance Sub-Study Cohort 1: Change from Baseline in PROMIS- Fatigue Short Form 7a T-score., Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants with endoscopic remission., Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving clinical remission by mMS, in the subset of participants who achieved clinical remission by mMs at the end of induction period (maintenance of clinical remission)., Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants with no abdominal pain by Numerical Rating Scale (NRS)., Pivotal Maintenance Sub-Study Cohort 1: Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score., Pivotal Maintenance Sub-Study Cohort 1: Incidence of UC-related hospitalizations., Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants with symptomatic (stool-frequency sub score [SFS] and = rectal bleeding sub score [RBS]) remission., Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving clinical remission and no steroid use from the baseline to the time of endpoint analysis., Pivotal Maintenance Sub-Study Cohort 1: Incidence of Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Adverse Events of Special Interest (TEAESIs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-Emergent Adverse Events (TEAEs) leading to permanent study intervention discontinuation., Pivotal Maintenance Sub-Study Cohort 1: Serum concentration of duvakitug measured over time., Pivotal Maintenance Sub-Study Cohort 1: Incidence of treatment-emergent Anti-Drug Antibodies (ADA) against duvakitug., Open-Label Extension Sub-Study: Incidence of Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Adverse Events of Special Interest (TEAESIs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-Emergent Adverse Events (TEAEs) leading to permanent study intervention discontinuation. Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving clinical remission by modified Mayo Score (mMS).

Начало: 09.02.2026 Възраст: от 18 г.

Austria, Belgium, Bulgaria +12 Sanofi-Aventis Recherche & Developpement 2025-521038-27-00

1 … 38 39 40 41 42 … 222